Published in Cancer Res on April 15, 2007
Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell (2012) 3.65
Copy number variation detection in whole-genome sequencing data using the Bayesian information criterion. Proc Natl Acad Sci U S A (2011) 2.72
A tumor suppressive coactivator complex of p53 containing ASC-2 and histone H3-lysine-4 methyltransferase MLL3 or its paralogue MLL4. Proc Natl Acad Sci U S A (2009) 2.06
Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc Natl Acad Sci U S A (2012) 1.82
The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol (2010) 1.80
Mutational profile of GNAQQ209 in human tumors. PLoS One (2009) 1.62
Rho guanine nucleotide exchange factors: regulators of Rho GTPase activity in development and disease. Oncogene (2013) 1.44
Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors. Clin Cancer Res (2012) 1.37
Evolution and dynamics of pancreatic cancer progression. Oncogene (2013) 1.25
Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. PLoS One (2012) 1.21
Genetic evolution of pancreatic cancer: lessons learnt from the pancreatic cancer genome sequencing project. Gut (2011) 1.20
Frequent alteration of MLL3 frameshift mutations in microsatellite deficient colorectal cancer. PLoS One (2011) 1.19
Eph receptors and ephrin ligands: important players in angiogenesis and tumor angiogenesis. J Oncol (2010) 1.17
Network-guided analysis of genes with altered somatic copy number and gene expression reveals pathways commonly perturbed in metastatic melanoma. PLoS One (2011) 1.09
Histone demethylases and cancer. Adv Cancer Res (2009) 1.05
An improved syngeneic orthotopic murine model of human breast cancer progression. Breast Cancer Res Treat (2014) 1.03
Cancer somatic mutations disrupt functions of the EphA3 receptor tyrosine kinase through multiple mechanisms. Biochemistry (2012) 1.01
Clinical relevance of Ephs and ephrins in cancer: lessons from breast, colorectal, and lung cancer profiling. Semin Cell Dev Biol (2011) 1.00
EphA receptor signaling--complexity and emerging themes. Semin Cell Dev Biol (2011) 1.00
Inherited predisposition to glioma. Neuro Oncol (2009) 0.99
Driver mutations of cancer epigenomes. Protein Cell (2014) 0.98
Molecular profiling of the "plexinome" in melanoma and pancreatic cancer. Hum Mutat (2009) 0.97
Mutated genes, pathways and processes in tumours. EMBO Rep (2010) 0.97
Molecular pathways in pancreatic carcinogenesis. J Surg Oncol (2012) 0.95
Loss of giant obscurins promotes breast epithelial cell survival through apoptotic resistance. FASEB J (2012) 0.94
OBSCN Mutations Associated with Dilated Cardiomyopathy and Haploinsufficiency. PLoS One (2015) 0.93
Very Long-term Survival Following Resection for Pancreatic Cancer Is Not Explained by Commonly Mutated Genes: Results of Whole-Exome Sequencing Analysis. Clin Cancer Res (2015) 0.93
Structural recognition of an optimized substrate for the ephrin family of receptor tyrosine kinases. FEBS J (2009) 0.93
Epigenetic modifications by dietary phytochemicals: implications for personalized nutrition. Pharmacol Ther (2012) 0.92
The Drosophila F-box protein Archipelago controls levels of the Trachealess transcription factor in the embryonic tracheal system. Dev Biol (2007) 0.92
Use of chromosome engineering to model a segmental deletion of chromosome band 7q22 found in myeloid malignancies. Blood (2010) 0.90
Obscurins: unassuming giants enter the spotlight. IUBMB Life (2013) 0.89
Requirement for MLL3 in p53 regulation of hepatic expression of small heterodimer partner and bile acid homeostasis. Mol Endocrinol (2011) 0.89
Epigenomic regulation of bile acid metabolism: emerging role of transcriptional cofactors. Mol Cell Endocrinol (2012) 0.86
Mutational profiling of kinases in glioblastoma. BMC Cancer (2014) 0.84
Absence of AKT1 mutations in glioblastoma. PLoS One (2009) 0.83
Pancreatic cancer genomics: insights and opportunities for clinical translation. Genome Med (2013) 0.82
Loss of giant obscurins from breast epithelium promotes epithelial-to-mesenchymal transition, tumorigenicity and metastasis. Oncogene (2014) 0.82
EphA3 functions are regulated by collaborating phosphotyrosine residues. Cell Res (2010) 0.82
Low frequency of MLL3 mutations in colorectal carcinoma. Cancer Genet Cytogenet (2009) 0.81
Mutations of the EPHB6 receptor tyrosine kinase induce a pro-metastatic phenotype in non-small cell lung cancer. PLoS One (2012) 0.81
Identification and characterization of alternative exon usage linked glioblastoma multiforme survival. BMC Med Genomics (2012) 0.81
MUFFINN: cancer gene discovery via network analysis of somatic mutation data. Genome Biol (2016) 0.80
Excess congenital non-synonymous variation in leukemia-associated genes in MLL- infant leukemia: a Children's Oncology Group report. Leukemia (2013) 0.80
Loss of EphB6 protein expression in human colorectal cancer correlates with poor prognosis. J Mol Histol (2014) 0.79
Neuroendocrine Merkel cell carcinoma is associated with mutations in key DNA repair, epigenetic and apoptosis pathways: a case-based study using targeted massively parallel sequencing. Neuroendocrinology (2014) 0.79
Interaction between MLL3 genetic polymorphisms, smoking, and alcohol drinking in laryngeal cancer: a case-control study. Cancer Med (2016) 0.78
Loss of the obscurin-RhoGEF downregulates RhoA signaling and increases microtentacle formation and attachment of breast epithelial cells. Oncotarget (2014) 0.78
Mutational profiling of kinases in human tumours of pancreatic origin identifies candidate cancer genes in ductal and ampulla of vater carcinomas. PLoS One (2010) 0.77
Contribution of the OBSCN nonsynonymous variants to aspirin exacerbated respiratory disease susceptibility in Korean population. DNA Cell Biol (2012) 0.76
Titin and obscurin: giants holding hands and discovery of a new Ig domain subset. J Mol Biol (2014) 0.76
Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling. Cancer Lett (2015) 0.75
Kinase analysis of penile squamous cell carcinoma on multiple platforms to identify potential therapeutic targets. Oncotarget (2017) 0.75
New insights into the functional consequences of ephrin A3 mutations in non-small cell lung cancer. Transl Lung Cancer Res (2013) 0.75
Improving Survival of Pancreatic Cancer. What Have We Learnt? Indian J Surg (2015) 0.75
Genome resequencing and bioinformatic analysis of SNP containing candidate genes in the autoimmune vitiligo Smyth line chicken model. BMC Genomics (2014) 0.75
Evidence for genetic association between chromosome 1q loci and predisposition to colorectal neoplasia. Br J Cancer (2017) 0.75
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
International network of cancer genome projects. Nature (2010) 20.35
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol (2010) 13.25
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol (2008) 11.73
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature (2012) 9.39
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature (2012) 8.77
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA (2010) 8.21
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat (2009) 7.68
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature (2002) 7.46
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol (2005) 7.43
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res (2007) 5.54
Colorectal cancer: mutations in a signalling pathway. Nature (2005) 5.42
MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol (2006) 5.40
Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat Genet (2009) 5.06
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res (2009) 4.82
Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol (2014) 4.76
Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science (2004) 4.67
Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst (2009) 4.42
Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol (2003) 4.31
New common variants affecting susceptibility to basal cell carcinoma. Nat Genet (2009) 4.15
Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol (2006) 4.13
A rare variant in MYH6 is associated with high risk of sick sinus syndrome. Nat Genet (2011) 3.94
A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov (2011) 3.86
Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci U S A (2004) 3.35
Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol (2013) 3.34
Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res (2009) 3.22
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res (2004) 3.20
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest (2010) 3.11
Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol (2009) 2.94
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov (2013) 2.87
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A (2010) 2.79
Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET. Clin Cancer Res (2013) 2.61
A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat Genet (2010) 2.56
Identification of low-frequency variants associated with gout and serum uric acid levels. Nat Genet (2011) 2.48
Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res (2011) 2.27
Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. J Clin Oncol (2013) 2.26
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One (2009) 2.18
Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers. Nat Genet (2002) 2.00
MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. J Invest Dermatol (2010) 1.93
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology (2009) 1.92
Branch-duct intraductal papillary mucinous neoplasms of the pancreas: to operate or not to operate? Gut (2006) 1.91
p21(WAF1/CIP1) mediates the growth response to TGF-beta in human epithelial cells. Cancer Biol Ther (2004) 1.90
Association of polymorphisms in the IL1B and IL2 genes with susceptibility and severity of systemic sclerosis. J Rheumatol (2007) 1.87
Establishment of the MAVER-1 cell line, a model for leukemic and aggressive mantle cell lymphoma. Haematologica (2006) 1.84
MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci U S A (2006) 1.82
Circulating autoantibodies to phosphorylated α-enolase are a hallmark of pancreatic cancer. J Proteome Res (2010) 1.81
The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol (2010) 1.80
Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci Transl Med (2014) 1.79
Identifying tumor origin using a gene expression-based classification map. Cancer Res (2003) 1.78
Ancestry-shift refinement mapping of the C6orf97-ESR1 breast cancer susceptibility locus. PLoS Genet (2010) 1.74
Alterations in vascular gene expression in invasive breast carcinoma. Cancer Res (2004) 1.68
Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene (2002) 1.67
Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses. Proc Natl Acad Sci U S A (2008) 1.66
HB-EGF/HER-1 signaling in bone marrow mesenchymal stem cells: inducing cell expansion and reversibly preventing multilineage differentiation. Blood (2005) 1.62
Mutational profile of GNAQQ209 in human tumors. PLoS One (2009) 1.62
European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. Hum Mol Genet (2011) 1.58
pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int J Cancer (2010) 1.58
BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene (2004) 1.58
DNA qualification workflow for next generation sequencing of histopathological samples. PLoS One (2013) 1.57
Gastrinoma (duodenal and pancreatic). Neuroendocrinology (2007) 1.55
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. J Natl Cancer Inst (2013) 1.54
IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo. Ann Neurol (2011) 1.53
Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. Clin Cancer Res (2012) 1.51
Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT. J Invest Dermatol (2009) 1.48
Endocrine neoplasms of the pancreas: pathologic and genetic features. Arch Pathol Lab Med (2009) 1.46
Clinical genetic testing for familial melanoma in Italy: a cooperative study. J Am Acad Dermatol (2009) 1.45
Expression and functional role of mGluR3 and mGluR5 in human astrocytes and glioma cells: opposite regulation of glutamate transporter proteins. Eur J Neurosci (2003) 1.44
PRL-3 phosphatase is implicated in ovarian cancer growth. Clin Cancer Res (2005) 1.43
Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol (2011) 1.42
Endothelin receptor antagonism prevents hypoxia-induced mortality and morbidity in a mouse model of sickle-cell disease. J Clin Invest (2008) 1.42
Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels. Hum Mutat (2013) 1.42
Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology (2007) 1.40
Phosphatase protein homologue to tensin expression and phosphatidylinositol-3 phosphate kinase mutations in colorectal cancer. Cancer Res (2005) 1.38
MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases. Endocr Relat Cancer (2010) 1.38
Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. Biochim Biophys Acta (2007) 1.38
Bone marrow stromal cells and the upregulation of interleukin-8 production in human T-cell acute lymphoblastic leukemia through the CXCL12/CXCR4 axis and the NF-kappaB and JNK/AP-1 pathways. Haematologica (2008) 1.35
Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. J Pathol (2014) 1.33